litlas
Log inCreate account

Alan Ashworth

Active 1979–2026

284
Papers
83,441
Citations
147
h-index
280
i10-index

Citations

Citations per year for Alan Ashworth1943: 1 citations1948: 1 citations1982: 1 citations1985: 1 citations1988: 1 citations1989: 5 citations1990: 4 citations1991: 10 citations1992: 25 citations1993: 51 citations1994: 96 citations1995: 122 citations1996: 209 citations1997: 312 citations1998: 373 citations1999: 342 citations2000: 286 citations2001: 308 citations2002: 257 citations2003: 241 citations2004: 324 citations2005: 337 citations2006: 433 citations2007: 494 citations2008: 603 citations2009: 697 citations2010: 1,064 citations2011: 1,036 citations2012: 979 citations2013: 937 citations2014: 971 citations2015: 985 citations2016: 1,000 citations2017: 1,042 citations2018: 1,009 citations2019: 2,820 citations2020: 3,323 citations2021: 2,975 citations2022: 2,327 citations2023: 1,618 citations2024: 2,320 citations2025: 1,145 citations2026: 40 citations1944–1947: no citations, so these years are not shown1949–1981: no citations, so these years are not shown1983–1984: no citations, so these years are not shown1986–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 10,024 citing papers, 28.7% of this breakdownUnited Kingdom: 3,595 citing papers, 10.3% of this breakdownChina: 3,141 citing papers, 9% of this breakdownGermany: 1,650 citing papers, 4.7% of this breakdownCanada: 1,414 citing papers, 4% of this breakdownFrance: 1,351 citing papers, 3.9% of this breakdownItaly: 1,297 citing papers, 3.7% of this breakdownAustralia: 1,044 citing papers, 3% of this breakdownNetherlands: 990 citing papers, 2.8% of this breakdownJapan: 941 citing papers, 2.7% of this breakdownSpain: 913 citing papers, 2.6% of this breakdownSwitzerland: 632 citing papers, 1.8% of this breakdown
0%28.7%Other 22.8%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology52.1%
  • Medicine40.3%
  • Immunology and Microbiology2.8%
  • Computer Science1.1%
  • Neuroscience1.1%
  • Engineering0.5%
  • Other2.1%

Topics

  • PARP inhibition in cancer therapy5.8%
  • DNA Repair Mechanisms5.3%
  • Cancer Genomics and Diagnostics3%
  • BRCA gene mutations in cancer2.9%
  • CRISPR and Genetic Engineering2.5%
  • Epigenetics and DNA Methylation2.1%
  • Other78.4%

Coauthors

All papers

Open in search
  1. PARP inhibitors: Synthetic lethality in the clinic

    Authors: Christopher J. Lord, Alan Ashworth - Science 2017 cited by 2,937

  2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

    Authors: Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M.B. Martin, Stephen P. Jackson, Graeme C.M. Smith, Alan Ashworth - Nature 2005 cited by 6,735

  3. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence

    Authors: Julia A. Belk, Winnie Yao, Nghi Ly, Katherine A. Freitas, Yanting Chen, Quanming Shi, Alfredo M. Valencia, Eric Shifrut, Nupura Kale, Kathryn E. Yost, Connor V. Duffy, Bence Dániel, Madeline A. Hwee, Zhuang Miao, Alan Ashworth, Crystal L. Mackall, Alexander Marson, Julia Carnevale, Santosha A. Vardhana, Ansuman T. Satpathy - Cancer Cell 2022 cited by 350

  4. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Authors: Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono - New England Journal of Medicine 2009 cited by 3,632

  5. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

    Authors: Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Pérez-López, Daniel Nava Rodrigues, Dan R. Robinson, Aurelius Omlin, Nina Tunariu, Gunther Boysen, Núria Porta, Penny Flohr, Alexa Gillman, Ines Figueiredo, Claire Paulding, George Seed, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed A. Hussain, Robert J. Jones, Tony Elliott, Ursula McGovern, Diletta Bianchini, Jane Goodall, Zafeiris Zafeiriou, Chris T. Williamson, Roberta Ferraldeschi, Ruth Riisnaes, Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi‐Mi Wu, Xuhong Cao, Rachel Brough, Helen N. Pemberton, Roger A’Hern, Amanda Swain, Lakshmi P. Kunju, Rosalind A. Eeles, Gerhardt Attard, Christopher J. Lord, Alan Ashworth, Mark A. Rubin, Karen E. Knudsen, Felix Y. Feng, Arul M. Chinnaiyan, Emma Hall, Johann S. de Bono - New England Journal of Medicine 2015 cited by 2,187

  6. Reprogramming human T cell function and specificity with non-viral genome targeting

    Authors: Theodore L. Roth, Cristina Puig-Saus, Ruby Yu, Eric Shifrut, Julia Carnevale, P. Jonathan Li, Joseph Hiatt, Justin D. Saco, Paige Krystofinski, Han Li, Victoria Tobin, David N. Nguyen, Michael R. Lee, Amy Putnam, Andrea L. Ferris, Jeff W. Chen, Jean-Nicolas Schickel, Laurence Pellerin, David Carmody, Gorka Alkorta‐Aranburu, Daniela del Gaudio, Hiroyuki Matsumoto, Montse Morell, Ying Mao, Min Cho, Rolen M. Quadros, Channabasavaiah B. Gurumurthy, Baz Smith, Michael Haugwitz, Stephen H. Hughes, Jonathan S. Weissman, Kathrin Schumann, Jonathan H. Esensten, Andrew P. May, Alan Ashworth, Gary M. Kupfer, Siri Atma W. Greeley, Rosa Bacchetta, Eric Meffre, Maria Grazia Roncarolo, Neil Romberg, Kevan C. Herold, Antoni Ribas, Manuel D. Leonetti, Alexander Marson - Nature 2018 cited by 871

  7. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

    Authors: David A. Quigley, Ha X. Dang, Shuang G. Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J. Alumkal, Adam Foye, Vishal Kothari, Marc D. Perry, Adina Bailey, Denise Playdle, Travis J. Barnard, Li Zhang, Jin Zhang, Jack Youngren, Marcin Cieślik, Abhijit Parolia, Tomasz M. Beer, George Thomas, Kim N., Martin Gleave, Nathan A. Lack, Amina Zoubeidi, Robert E. Reiter, Matthew B. Rettig, Owen N. Witte, Charles J. Ryan, Lawrence Fong, Won Bae Kim, Terence W. Friedlander, Jonathan Chou, Haolong Li, Rajdeep Das, Hui Li, Ruhollah Moussavi-Baygi, Hani Goodarzi, Luke A. Gilbert, Primo N. Lara, Christopher P. Evans, Theodore C. Goldstein, Joshua M. Stuart, Scott A. Tomlins, Daniel E. Spratt, R. Keira Cheetham, Donavan T. Cheng, Kyle Kai‐How Farh, Julian Gehring, Jörg Hakenberg, Arnold Liao, Philip G. Febbo, John Shon, Brad Sickler, Serafim Batzoglou, Karen E. Knudsen, Housheng Hansen He, Jiaoti Huang, Alexander W. Wyatt, Scott M. Dehm, Alan Ashworth, Arul M. Chinnaiyan, Christopher A. Maher, Eric J. Small, Felix Y. Feng - Cell 2018 cited by 759

  8. Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function

    Authors: Eric Shifrut, Julia Carnevale, Victoria Tobin, Theodore L. Roth, Jonathan M. Woo, Christina Bui, P. Jonathan Li, Morgan E. Diolaiti, Alan Ashworth, Alexander Marson - Cell 2018 cited by 581

  9. BRCAness revisited

    Authors: Christopher J. Lord, Alan Ashworth - Nature reviews. Cancer 2016 cited by 1,250

  10. The DNA damage response and cancer therapy

    Authors: Christopher J. Lord, Alan Ashworth - Nature 2012 cited by 1,829

  11. Synthetic lethality as an engine for cancer drug target discovery

    Authors: Alan Huang, Levi A. Garraway, Alan Ashworth, Barbara L. Weber - Nature Reviews Drug Discovery 2019 cited by 469

  12. ADP‐ribosyltransferases, an update on function and nomenclature

    Authors: Bernhard Lüscher, Ivan Ahel, Matthias Altmeyer, Alan Ashworth, Péter Bai, Paul Chang, Michael S. Cohen, Daniela Corda, Françoise Dantzer, Matthew D. Daugherty, Ted M. Dawson, Valina L. Dawson, Sebastian Deindl, Anthony R. Fehr, Karla L. H. Feijs, Dmitri V. Filippov, Jean‐Philippe Gagné, Giovanna Grimaldi, Sebastian Guettler, Nícolas C. Hoch, Michael O. Hottiger, Patricia Korn, W. Lee Kraus, Andreas G. Ladurner, L. Lehtiö, Anthony K. L. Leung, Christopher J. Lord, Aswin Mangerich, Ivan Matić, Jason Matthews, George‐Lucian Moldovan, Joel Moss, Gioacchino Natoli, Michael L. Nielsen, Mario Niepel, F. Nolte, John M. Pascal, Bryce M. Paschal, Krzysztof Pawłowski, Guy G. Poirier, Susan Smith, Gyula Timinszky, Zhao‐Qi Wang, José Yélamos, Xiaochun Yu, Roko Žaja, Mathias Ziegler - FEBS Journal 2021 cited by 327

  13. RASA2 ablation in T cells boosts antigen sensitivity and long-term function

    Authors: Julia Carnevale, Eric Shifrut, Nupura Kale, William A. Nyberg, Franziska Blaeschke, Yan Yi Chen, Zhongmei Li, Sagar P. Bapat, Morgan E. Diolaiti, Patrick C. O’Leary, Shane Vedova, Julia A. Belk, Bence Dániel, Theodore L. Roth, Stefanie Bachl, Alejandro Allo Anido, Brooke Prinzing, Jorge Ibañez-Vega, Shannon Lange, Dalia Haydar, Marie Luetke-Eversloh, Maëlys Born-Bony, Bindu Hegde, Scott C. Kogan, Tobias Feuchtinger, Hideho Okada, Ansuman T. Satpathy, Kevin Shannon, Stephen Gottschalk, Justin Eyquem, Giedre Krenciute, Alan Ashworth, Alexander Marson - Nature 2022 cited by 223

  14. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

    Authors: Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma, Amy Dréan, Feifei Song, Radoslav Aleksandrov, Maria I. Harrell, Malini Menon, Rachel Brough, James Campbell, Jessica Frankum, Michael Ranes, Helen N. Pemberton, Rumana Rafiq, Kerry Fenwick, Amanda Swain, Sebastian Guettler, Jung-Min Lee, Elizabeth M. Swisher, Stoyno Stoynov, Kosuke Yusa, Alan Ashworth, Christopher J. Lord - Nature Communications 2018 cited by 447

  15. The DNA methylation landscape of advanced prostate cancer

    Authors: Shuang G. Zhao, William S. Chen, Haolong Li, Adam Foye, Meng Zhang, Martin Sjöström, Rahul Aggarwal, Denise Playdle, Arnold Liao, Joshi J. Alumkal, Rajdeep Das, Jonathan Chou, Junjie T. Hua, Travis J. Barnard, Adina Bailey, Eric D. Chow, Marc D. Perry, Ha X. Dang, Rendong Yang, Ruhollah Moussavi-Baygi, Li Zhang, Mohammed Alshalalfa, S. Laura Chang, Kathleen E. Houlahan, Yu-Jia Shiah, Tomasz M. Beer, George Thomas, Kim N., Martin Gleave, Amina Zoubeidi, Robert E. Reiter, Matthew B. Rettig, Owen N. Witte, M. Yvonne Kim, Lawrence Fong, Daniel E. Spratt, Todd M. Morgan, Rohit Bose, Franklin W. Huang, Hui Li, Lisa N. Chesner, Tanushree Shenoy, Hani Goodarzi, Irfan A. Asangani, Shahneen Sandhu, Joshua M. Lang, Nupam P. Mahajan, Primo N. Lara, Christopher P. Evans, Phillip G. Febbo, Serafim Batzoglou, Karen E. Knudsen, Housheng Hansen He, Jiaoti Huang, Wilbert Zwart, J Costello, Jianhua Luo, Scott A. Tomlins, Alexander W. Wyatt, Scott M. Dehm, Alan Ashworth, Luke A. Gilbert, Paul C. Boutros, Kyle Kai‐How Farh, Arul M. Chinnaiyan, Christopher A. Maher, Eric J. Small, David A. Quigley, Felix Y. Feng - Nature Genetics 2020 cited by 353

  16. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy

    Authors: Jonathan Chou, David A. Quigley, Troy M. Robinson, Felix Y. Feng, Alan Ashworth - Cancer Discovery 2020 cited by 293

  17. PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer

    Authors: Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, Julien Adam, Daphné Morel, Marlène Garrido, Andrew Lamb, Clémence Henon, Nicolas Dorvault, Mathieu Rouanne, Rebecca Marlow, Ilirjana Bajrami, Marta Llorca Cardeñosa, Asha Konde, Benjamin Besse, Alan Ashworth, Stephen J. Pettitt, Syed Haider, Aurélien Marabelle, Andrew Tutt, Jean‐Charles Soria, Christopher J. Lord, Sophie Postel‐Vinay - Journal of Clinical Investigation 2018 cited by 324

  18. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

    Authors: Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeffrey C. Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord - Nature Communications 2016 cited by 387

  19. Resistance to therapy caused by intragenic deletion in BRCA2

    Authors: Stacey L. Edwards, Rachel Brough, Christopher J. Lord, Rachael Natrajan, Radost Vatcheva, Douglas A. Levine, Jeff Boyd, Jorge S. Reis‐Filho, Alan Ashworth - Nature 2008 cited by 1,012

  20. Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA

    Authors: Gulfem D. Guler, Yuhong Ning, Chin‐Jen Ku, Tierney Phillips, Erin McCarthy, Christopher K. Ellison, Anna Bergamaschi, François Collin, Paul Lloyd, Aaron Scott, Michael Antoine, Wendy Wang, Kim Chau, Alan Ashworth, Stephen R. Quake, Samuel Levy - Nature Communications 2020 cited by 186

  21. Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking

    Authors: M. Schuller, G.J. Correy, Stefan Gahbauer, D. Fearon, Taiasean Wu, Roberto Efraín Díaz, I.D. Young, Luan Carvalho Martins, Dominique H. Smith, Ursula Schulze‐Gahmen, Tristan W. Owens, Ishan Deshpande, Gregory E. Merz, Aye C. Thwin, J.T. Biel, Jessica K. Peters, Michelle Moritz, Nadia Herrera, Huong T. Kratochvil, A. Aimon, James M. Bennett, J. Brandão-Neto, Aina E. Cohen, Alexandre Dias, A. Douangamath, Louise Dunnett, Oleg Fedorov, Matteo P. Ferla, Martin R. Fuchs, T.J. Gorrie-Stone, James M. Holton, Michael G. Johnson, T. Krojer, G. Meigs, A.J. Powell, J.G.M. Rack, V.L. Rangel, Silvia Russi, R. Skyner, Clyde A. Smith, Alexei S. Soares, Jennifer L. Wierman, Kang Zhu, Peter O’Brien, Natalia Jura, Alan Ashworth, John J. Irwin, Michael C. Thompson, Jason E. Gestwicki, F. von Delft, Brian K. Shoichet, James S. Fraser, Ivan Ahel - Science Advances 2021 cited by 208

  22. Identification of the breast cancer susceptibility gene BRCA2

    Authors: Richard Wooster, Graham R. Bignell, Jonathan Lancaster, Sally Swift, Sheila Seal, Jonathan Mangion, Nadine Collins, Simon G. Gregory, Curtis Gumbs, Gos Micklem, Rita Barfoot, Rifat Hamoudi, Sandeep Patel, Catherine Rices, Patrick J. Biggs, Yasmin Hashim, Amanda Smith, Frances Connor, Aðalgeir Arason, Jūlı́us Guðmundsson, D. Ficenec, David P. Kelsell, Deborah Ford, Patricia N. Tonin, D. Timothy Bishop, Nigel K. Spurr, Bruce A.J. Ponder, Rosalind A. Eeles, Julian Peto, Peter Devilee, Cees J. Cornelisse, Henry T. Lynch, Steven A. Narod, Gilbert Lenoir, V Egilsson, Rosa Bjork Barkadottir, Douglas F. Easton, David Bentley, P. Andrew Futreal, Alan Ashworth, Michael R. Stratton - Nature 1995 cited by 3,663

  23. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

    Authors: Alan Ashworth, Christopher J. Lord - Nature Reviews Clinical Oncology 2018 cited by 421

  24. Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

    Authors: Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Katarzyna Kluzek, Aneta Białkowska, Sally Swift, Sabrina Giavara, Mark J. O’Connor, Andrew Tutt, Małgorzata Z. Zdzienicka, Graeme C.M. Smith, Alan Ashworth - Cancer Research 2006 cited by 1,305